Pharming Group (OTCMKTS:PHGUF) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.

Several other equities analysts have also commented on PHGUF. HC Wainwright reiterated a “buy” rating on shares of Pharming Group in a research report on Thursday, October 26th. Zacks Investment Research upgraded shares of Pharming Group from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Friday, October 27th.

Shares of Pharming Group (OTCMKTS PHGUF) traded up $0.01 during trading hours on Friday, hitting $1.45. 10,000 shares of the company were exchanged, compared to its average volume of 44,699. The company has a debt-to-equity ratio of 11.72, a current ratio of 1.77 and a quick ratio of 1.27. Pharming Group has a 12-month low of $0.25 and a 12-month high of $1.58.

WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/02/pharming-group-phguf-rating-lowered-to-sell-at-valuengine.html.

About Pharming Group

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pharming Group NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group NV and related companies with MarketBeat.com's FREE daily email newsletter.